Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-09
-
Prostate cancer is the second leading cause of cancer relate
2025-02-28
Prostate cancer is the second leading cause of cancer-related death in men in the United States [25]. Similar to pancreatic cancer, prostate cancer has few diagnostic options available, particularly to differentiate indolent from aggressive disease. Axl is also overexpressed in ∼50% of prostate canc
-
The earliest appearance of tumors occurred at
2025-02-28
The earliest appearance of tumors occurred at 12 months and the latest at 24 months, with an average onset at 18 months (Fig. 1B). This would be roughly equivalent to cancer presenting in a patient between 60 and 70 years of age. In transgenic animals, autotaxin GX-674 was relatively increased in s
-
Crohn s disease an inflammatory bowel disease
2025-02-28
Crohn’s disease, an inflammatory bowel disease that affects the gastrointestinal (GI) tract, is characterized by a polymorphism in ULK1 autophagy gene due to the presence of single nucleotide polymorphisms (SNPs). Thus, the autophagic process is impaired during the disease. The mutations in the leuc
-
br Oxidative microbe killing and V ATPase Oxidative killing
2025-02-28
Oxidative microbe killing and V-ATPase Oxidative killing of phagocytosed microorganisms is predominately achieved through the uptake of large quantities of molecular oxygen by the infected cell and the activity particularly of the NADPH oxidase complex on phagosomes (Savina et al., 2006) and the
-
The interaction of ATR ATRIP with
2025-02-28
The interaction of ATR-ATRIP with RPA-coated ssDNA is sufficient for ATR-ATRIP recruitment to DNA lesions, but it is not sufficient to fully activate ATR. In response to DNA damage, the heterotrimeric ring-shaped complex 9-1-1 (RAD9-RAD1-HUS1 in humans; Ddc1-Rad17-Mec3 in S. cerevisiae) is loaded at
-
In this study we first determined whether AIF
2025-02-28
In this study, we first determined whether AIF in bovine LT muscle is expressed and the mitochondria released AIF-mediated apoptosis during postmortem aging. For apoptotic issues, the mitochondrial outer membrane is permeabilized, and AIF translocates to the cytosol and to the nucleus, where it indu
-
Obesity is associated with chronic low grade inflammation re
2025-02-28
Obesity is associated with chronic low-grade 5-BrdU resulting from increased M1 macrophage infiltration into adipose tissue, which can subsequently lead to the development of insulin resistance. Previously, we reported that LFE and FSB both reduced body weight gain in high fat diet-induced obese mic
-
First the complete canonical brain original RAS Angiotensino
2025-02-28
First, the complete canonical brain original RAS (Angiotensinogen, Renin, Angiotensin I, Angiotensin Converting Enzyme (ACE), Angiotensin II) has not been conclusively identified in any specific cell type within the brain [1]. Validated evidence for the presence of brain Angiotensinogen and ACE was
-
The G R mutation is located at the solvent
2025-02-28
The G1202R mutation is located at the solvent front of the ALK kinase domain adjacent to the inhibitor's binding pocket. Although barely reported in the setting of crizotinib resistance, it has emerged as the most refractory mutation to both the first- and second-generation ALK inhibitors. The large
-
Several ceritinib resistant mutations following
2025-02-28
Several ceritinib-resistant mutations following the second-line treatment of ALK+-NSCLC have been discovered [64]. These mutations include C1156Y, F1174L, and L1152R, which were first observed in crizotinib-resistant tumor samples. The G1202R ceritinib-resistant mutation occurs within the hinge and
-
For patients who have taken advantage of
2025-02-28
For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
-
Differentiation of skeletal myoblasts is a tightly orchestra
2025-02-28
Differentiation of skeletal myoblasts is a tightly orchestrated process that involves myoblast proliferation, erythromycin ethylsuccinate suspension withdrawal, expression of muscle-specific genes, and fusion into multinucleated myofibers (Horsley and Pavlath, 2004; Krauss, 2010). The maintenance o
-
Young et al described the role
2025-02-28
Young et al. [40] described the role of adenine monophosphate-activated protein kinase (AMPK) in the translocation of GLUT4 in the heart. The AMPK is activated during muscle contraction [74] by converting AMP to ATP. The adenosine analog, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), is a c
-
br Therapeutic advantages and clinical
2025-02-27
Therapeutic advantages and clinical implications of caffeine treatment in ROP The demonstration of the role of the adenosine receptor in development of ROP and protection by caffeine suggests two potential therapeutic strategies with high translational potential: a) modification of caffeine treat
-
The cytoplasmic domain of muscle AChR is not accessible to
2025-02-27
The cytoplasmic domain of muscle AChR is not accessible to Epicatechin derivative in vivo. Theoretically, therapy with the cytoplasmic domains should be safe. Safety is demonstrated by the facts that: (1) rats repeatedly immunized with the cytoplasmic domains in TiterMax adjuvant do not develop EAM